ArticleNanoscale advances2019
The interplay between size and valence state on the antibacterial activity of sub-10 nm silver nanoparticles.
Article in Nanoscale advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Antibacterial Efficiency and Osteoblast Viability of Ag/AgO/AgACS omega · 2026Article
- De Novo Design Strategies of Nanomedicines for Diabetic Wound Microenvironment Remodeling.BME frontiers · 2026Review
- Sustainable Synthesis of Silver Nanoparticles (Chemical vs Biological) and Their Antimicrobial Activity against Clinical Pathogens.ACS omega · 2025Article
- Targeting ESKAPE pathogens with ZnS and Au@ZnS Core-Shell nanoconjugates for improved biofilm control.Scientific reports · 2025Article
- The Acid-Buffered Engineered Gel Promotes In Vitro Cutaneous Healing and Fights Resistant Bacteria in Wounds.Pharmaceutics · 2024Article
- Recent advances in nanoantibiotics against multidrug-resistant bacteria.Nanoscale advances · 2023Review
- The efficacy of biosynthesized silver nanoparticles against Pseudomonas aeruginosa isolates from cystic fibrosis patients.Scientific reports · 2023Article
- Smart Methylcellulose Hydrogels for pH-Triggered Delivery of Silver Nanoparticles.Gels (Basel, Switzerland) · 2022Article
- Eradication of Mature Bacterial Biofilms with Concurrent Improvement in Chronic Wound Healing Using Silver Nanoparticle Hydrogel Treatment.Biomedicines · 2021Article
- Combination of Au-Ag Plasmonic Nanoparticles of Varied Compositions with Carbon Nitride for Enhanced Photocatalytic Degradation of Ibuprofen under Visible Light.Materials (Basel, Switzerland) · 2021Article
- pH-Responsive "Smart" Hydrogel for Controlled Delivery of Silver Nanoparticles to Infected Wounds.Antibiotics (Basel, Switzerland) · 2021Article
- Quality-by-Design Approach for the Development of Nano-Sized Tea Tree Oil Formulation-Impregnated Biocompatible Gel with Antimicrobial Properties.Pharmaceutics · 2020Article
- The Impact of Engineered Silver Nanomaterials on the Immune System.Nanomaterials (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silver nanoparticles (AgNPs) have attracted enormous interest because of their excellent antibacterial properties, low cytotoxicity and limited evidence for resistance. As a general trend, smaller nanoparticles are considered to have stronger antibacterial activity. In this work we investigate whether this trend is valid for the sub-10 nm region by designing and synthesising three types of sub-10 nm AgNPs (∼1.87, ∼2.93 and ∼6.53 nm) to reveal the influence of size, valence state and structure on the antibacterial potency of AgNPs. We found that NPs with a size of ∼2.93 nm having a high concentration of silver in the first valence state presented the highest bacterial killing potency as well as low cytotoxicity to mammalian cells. The new insights presented in this study open future avenues for the engineering of highly potent silver nanoantibiotics that can be incorporated into future advanced medical devices and therapies capable of protecting patients from infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.